7
Views
0
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Curative treatment for recurrent and metastatic cervical cancer

&
Pages 521-523 | Published online: 10 Jan 2014
 

Abstract

Evaluation of: Liu SP, Huang X, Ke GH, Huang XW. 3D radiation therapy or intensity-modulated radiotherapy for recurrent and metastatic cervical cancer: the Shanghai Cancer Hospital Experience. PLoS ONE 7(6), e40299 (2012).

Metastatic and recurrent cervical cancer is generally considered incurable. Chemotherapy is the standard treatment modality, and chemotherapy has improved through randomized trials. Median survival with the best chemotherapy doublet is 12.9 months. In cases when surgery is not successful, prolonged survival may result with modern radiotherapy techniques. Liu et al. report a 3-year progression-free survival rate of 65%. Attention to radiotherapy details, such as avoidance of treatment delays, use of sensitizing chemotherapy and appropriate use of brachytherapy, and correct volumes and doses should be employed. For select patients with recurrent or metastatic cervical cancer, modern radiotherapy may be a good option.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Log in via your institution

Log in to Taylor & Francis Online

There are no offers available at the current time.

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.